momentum continu w/
horizon pt
amid rocki day earn deliv doctor order
post anoth strong quarter highlight signific ep beat vs
expect revenu million grew y/i came
estim despit market concern come quarter instrument revenu
beat expect million help affirm convict multi-year
novaseq replac cycl still earli inning consum revenu
strong y/i still signific runway toward long-term target
per instrument base may survey revenu beat
flow adjust oper margin expand y/i
came expect oper expens roughli flat
percentag revenu y/i mix benefit strength higher margin recur
revenu drove improv gross margin adj ep beat
street forecast
believ good visibl sustain mid-teen revenu growth
momentum driven popul sequenc initi traction
clinic custom growth china detail us program
popul sequenc initi see report takeaway
field broad institut increas convict lt trajectori
valid margin leverag demonstr last two quarter
convict compani abl translat revenu growth
faster earn growth time look toward remaind view
fourth quarter guidanc conserv note third straight quarter
manag simpli rais ep guidanc line quarterli beat despit
view momentum build context view recent share weak
attract entri point share sinc versu
reiter overweight rate rais price
quarterli annual ep usd
consensu number thomson reuter receiv gmt
barclay capit inc and/or one affili seek busi
compani cover research report result investor awar
firm may conflict interest could affect object report investor
consid report singl factor make invest decis
rais usd
return equiti ttm
link barclay live interact chart
overweight leader next
gener sequenc project
signific growth driven larg research studi
nascent opportun clinic diagnost
signific competit moat rel
competit given brand scale
growth forseeabl futur
compani instal base grow higher
consum revenu contribut margin
leverag estim upsid case
reflect upsid ep
growth ultim depend
custom fund includ govern grant
nih well clinic reimburs lower
downsid case reflect downsid
ep
margin return data
balanc sheet cash flow
equival
short long-term debt
chang work capit
flow oper
valuat leverag metric
amid rocki day earn deliv doctor order post
anoth strong quarter highlight signific ep beat vs expect
revenu million grew y/i came estim despit market
concern come quarter instrument revenu beat expect
million help affirm convict multi-year novaseq replac cycl
still earli inning consum revenu strong y/i still
signific runway toward long-term target per instrument base
may survey revenu beat flow adjust oper
margin expand y/i came expect
oper expens roughli flat percentag revenu y/i mix benefit
strength higher margin recur revenu drove improv gross
margin adj ep beat street forecast
believ good visibl sustain mid-teen revenu growth
momentum driven popul sequenc initi traction clinic
custom growth china detail us program
popul sequenc initi see report takeaway field
broad institut increas convict lt trajectori valid
margin leverag demonstr last two quarter convict
compani abl translat revenu growth faster earn growth
time look toward remaind view fourth quarter guidanc
conserv note third straight quarter manag simpli rais ep
guidanc line quarterli beat despit view momentum build
context view recent share weak attract entri point illumina
share sinc versu reiter overweight
rate rais price
increas price target given higher earn forecast
convict sustain demand novaseq platform price
target repres adj ep forecast target multipl unchang
base histor ratio earn growth project high-teen
forese futur prior price target repres prior
adj ep forecast
histor valuat price earn yr earn growth yr compound-annual-growth-rate
follow strong result rais ep guidanc compani
technic maintain revenu growth forecast around
commentari would flat slightli sequenti would mathemat
impli round compani post revenu ahead
guidanc call revenu flat slightli believ maintain
guidanc due million stock order china pull forward
consist previou guidanc expect place novaseq
non-gaap ep expect rang
midpoint prior guidanc midpoint ep guidanc repres growth
y/i anticip gross margin modestli earn
note guidanc includ dilut helix non-gaap tax rate
rang
expect revenu flat slightli sequenti despit
roughli million revenu china pull million
million result compani expect sequenti decreas sequenc
consum sequenc instrument revenu expect increas sequenti due
larg direct-to-consum order microarray instrument anticip
sequenti declin microarray revenu declin microarray instrument
forecast partial off-set increas microarray consum guid
toward gross margin lowest level year due mix oper expens
increas meaning percentag revenu
reiter novaseq placement expect unit
expect compani place instrument bring cumul
number novaseq placement benefit million stock
order mostli novaseq chines custom ahead futur tariff ceo
desouza note current tariff instrument tariff
consum demand driven strength compani flow cell
demand flow cell launch februari continu ramp illumina
continu confid novaseq expand whole-genom sequenc
market note third fourth novaseq custom new high
throughput sequenc sequenc whole interestingli novaseq custom
spend consum high throughput
sequenc compani still believ novaseq upgrad cycl span
multipl year major approxim high throughput custom
yet adopt novaseq regard futur desouza note
compani continu expect place novaseq
model forecast novaseq placement averag
consum pull-through follow expect placement
assum novaseq place repres replac least
one hiseq compani start see cannib hiseq custom well
given rel advantag novaseq forecast million novaseq
revenu year launch compar million nextseq
revenu million hiseq revenu year launch
assumpt model place novaseq per year hiseq
hiseq decommiss persist beyond given multi-year adopt util
increas per novaseq end model million
survey averag sinc assum new custom add lower overal average
barclay research revenu build
pleas see survey
say elast
upgrad ow
remind survey march-april show signific
demand novaseq continu expect major custom transit toward
platform custom spoke broadli expect de-commiss
hiseq hiseq instal base novaseq addit replac least
instrument across board shown novaseq instal base custom
spoke expect doubl today next year
segmentarray y/i miniseq instal y/i y/i stack y/i product y/i instrument instrument instrument instrument instrument miniseq instrument y/i y/i product product y/i product y/i servic y/i y/i consum instrument barclay illumina inc
expect lead signific reduct hiseq instrument
hiseq instrument collect decreas one custom transit
fleet nextseq onto novaseq instrument interestingli speak one
custom alreadi sold two novaseq anoth lab made
strateg pivot focu bioinformat cater custom buy novaseq
proprietari novaseq custom survey show major transit toward novaseq platform
novaseq custom survey expect substanti increas volum
sequenc next two year driven larg popul sequenc studi
increas cost effect exom sequenc substanti excit
around larg popul sequenc project sever referenc includ nih
us million genom initi us uk genom initi exom
grail liquid biopsi clinic trial could sequenc genom
regeneron announc would sequenc exom biobank
next month build volum total center survey describ
impli increas genom increas
exom collect number sampl
sequenc would increas anoth
custom proprietari survey expect volum growth
custom survey expect weight averag budget increas
custom expect budget declin next year broad
rang expect growth matur center project growth
rapidli grow sequenc custom project growth one smaller
research custom cite flat budget use novaseq cost save drive offset
amount volum coverag driver sequenc growth almost everi
custom use depth everi custom expect spend least million per
year consum novaseq weight averag million
believ unlik actual attain level overal instal base
averag sinc new custom addit drag overal novaseq averag
model project million novaseq util per instrument end
result self-report back envelop math suggest
decent approxim compar net instrument add decommiss
project novaseq util would suggest custom survey
increas consum spend gb sequenc
estim custom proprietari novaseq survey increas sequenc spend
revenu grew y/i million expect specif
better expect demand array instrument well array
consum drove revenu beat geograph perspect growth
broad-bas quarter growth unit state growth emea
growth asia-pacif region specif growth china
strength america driven demand sequenc result emea
benefit sequenc program genom england
utilizationrev mmpull-through per inst per gbinstal base revsgb seq mm instal base revsgb seq mm revsgb yeary/i chang barclay illumina inc
revenu y/i growth
continu believ china long-term structur growth driver
life scienc research sequenc fit natur countri ambit tackl
long-term societ need transit industri economi servic
economi better compet market china repres
revenu dwarf larger economi like unit state
europ said market experienc signific growth
believ market sustain growth
next sever year eclips billion revenu
expect china drive substanti growth number year
revenu increas y/i million total revenu
consum grew quarter strength across low medium high
throughput analyz note novaseq continu grow quickli
flow cell repres largest revenu contributor high-throughput
sequenc famili inclus million one-tim stock order addit
flow cell see strong growth flow cell nextseq
util came high end guid rang miseq
miniseq util fell within guidanc rang respect given
on-going novaseq upgrad cycl hiseq consum revenu continu declin y/i
instrument revenu increas y/i servic revenu strong
novaseq high throughput sequenc platform custom focus whole-
genom sequenc advantag rel legaci hiseq hiseq product
line instal base hiseq hiseq instrument compani
address larg market opportun base instrument sale alon upsid
would driven market expans drive higher consum revenu
said placement cannib exist instrument consum opportun
would limit note consum cost per sampl like go
applic mean consum revenu could actual declin
per-box basi view launch make sens revolutionari
product aim drive replac cycl put rest concern
around revenu visibl near term longer term overcapac concern
like remain compani tri expand market beyond current instal
design system larg market opportun mind note
system allow highest-throughput achiev lower sequenc cost
much lower capit commit rel hiseq hiseq
compani believ architectur novaseq platform eventu
allow achiev genom system use newli develop
company/systemlaunchedinstru costrun costrun lengthrun speedthroughputpric per gbilluminaiseq fisher life ion day all-in n/an/abgi complet genomicsrevoloc ii long nanopor barclay illumina inc
flow cell allow higher-throughput increas speed-to-result
maintain accuraci earlier system compani launch novaseq
three flow cell option three flow cell throughout
capabl hiseq respect modestli
reduc speed-to-result hiseq day day novaseq
price capabl run three flow cell earn
announc cancel novaseq flow cell
custom primarili demand novaseq instrument
hiseq anticip demand hiseq weaker quarter custom
opt novaseq platform importantli focus convert
exist hiseq custom novaseq remind hiseq launch
per system januari announc launch
hiseq enhanc leverag capabl hiseq
system hiseq price reagent price per gb
similarli hiseq price provid half output lower
reagent costs/fast run time base commentari assum util
low end compani guid rang per instrument
hiseq consum expect trend downward throughout remaind
hiseq launch novaseq plan drive replac cycl
hiseq custom come year launch hiseq
sequenc whole human genom compani market product
 sell ten instrument increas throughput larg genom center
reach covet genom price system million
note hiseq consum revenu continu steadi declin
project transit novaseq expect signific replac cycl
instrument follow recent launch flow cell said
compani note number custom need finish current project
januari announc sell hiseq five system
configur known hiseq hiseq allow product center
adopt high-throughput whole genom sequenc lower capit invest
 full util set-up estim sequenc
genom year compani sell hiseq system million
addit hiseq xs million thereaft sequenc cost per gb
approxim versu hiseq
nextseq launch nextseq system fill nich product
portfolio hiseq miseq instrument product flex whole
human genom sequenc target panel price per system
estim compani place nextseq global pull-through
high end guid rang
also launch nextseq combin microarray scan
nextseq sequenc system initi array qualifi system
cytogenet pgd applic expect enabl broad rang
applic reproduct health genet health oncolog adapt
allow lab gain access array sequenc singl capital-expenditure
miseq miseq util fell within compani guid rang quarter sinc
launch miniseq encourag lower expect level
miseq cannib ultim believ market desktop
instrument minimum estim place though
could make argument market size product price
unit expect annual pull-through
miniseq/iseq launch januari miniseq compani smallest
benchtop sequenc design target sequenc applic smaller lab
cost instrument roughli pull number quarter
rang model current instal base miniseq iseq
instrument earli januari announc iseq launch
expand portfolio breadth lower-throughput end sequenc
market compani describ iseq inexpens fast easi use sequenc
iseq target address market potenti custom rang
current owner new-to- custom iseq gener million
read greater per run run-tim rang hour price
per sampl rang addit sequenc cost less
instal custom less one hour shipment iseq
began end note first full quarter launch
better expect
array revenu increas y/i quarter million strength driven
primarili instrument consum respect servic
revenu declin quarter similarli recent trend demand driven
strength direct-to-consum market well global research applic
includ genotyp epigenet specif one custom place larg instrument
order anticip high demand test holiday season remind
dtc test compani notabl
ancestrydna compani also supplier dtc compani run volum in-
hous partner laboratori
gener revenu consum driven
strength array consum look back increas instal
base instrument market consum pull follow servic revenu
revenu grew y/i growth driven servic
mix revenu instrument vs recur
improv y/i driven posit mix within sequenc
consum compani non-gaap gross margin y/i
gross margin expect modestli keep mind better margin
consum revenu grew y/i revenu outpac servic growth
instrument revenu declin y/i ebitda margin
 ex-comp declin y/i revenu sg ex-comp
decreas y/i revenu put togeth total oper
expens sg stock-bas comp declin y/i revenu
helix account sg percentag revenu
non-gaap sg revenu
non-gaap ep increas y/i compani leverag strong top line
perform y/i margin improv deliv solid earn growth
compani tax rate benefit favor prior year return adjust record
result ep came estim addit ep
impact dilut helix quarter independ tax benefit
quarterli non-gaap ep y/i growth
y/i growthnon-gaap epsepsy/i growth barclay illumina inc
 except ep reportedincom profit base ebitda ebit pre-tax pre-tax tax net net researchprior yearprior quarter barclay inc
estestestestestestestestestincom statement growth growth growth growth growth growth y/i growth product revenu ex product revenu inc product revenu inc servic servic gross gross margin inc gross margin inc growth gener growth base sg stock base ebitda growth oper incom ebit growth invest debt expens pre-tax pre-tax growth incom tax non-control net net growth incom per basic ep inc non-cash growth interest net net growth growth net net net incom net barclay illumina inc
meehan cfa herebi certifi view express research report accur reflect person view
subject secur issuer refer research report part compens directli indirectli relat
specif recommend view express research report
